Medical Editor: John P. Cunha, DO, FACOEP
Arnuity Ellipta (fluticasone furoate) Inhalation Powder is a corticosteroid used for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Common side effects of Arnuity Ellipta Inhalation Powder include:
- breathing problems (bronchitis),
- cold symptoms,
- upper respiratory tract infection,
- sore throat,
- runny or stuffy nose,
- sinus infection (sinusitis),
- thrush (yeast infection of the mouth),
- muscle pain,
- sore throat, and
- flu-like symptoms
Arnuity Ellipta should be administered as 1 inhalation once daily by the orally inhaled route. Arnuity Ellipta may interact with azole antifungals, antibiotics, antiretroviral medications, conivaptan, and nefazodone. Tell your doctor all medications and supplements you use. During pregnancy, Arnuity Ellipta should be used only if prescribed. Tell your doctor if you become pregnant while taking Arnuity Ellipta. It is unknown if this drug passes into breast milk, however, other corticosteroids pass into breast milk. Consult your doctor before breastfeeding.
Our Arnuity Ellipta (fluticasone furoate) Inhalation Powder Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Systemic and local corticosteroid use may result in the following:
- Candida albicans infection [see WARNINGS AND PRECAUTIONS]
- Immunosuppression [see WARNINGS AND PRECAUTIONS]
- Hypercorticism and adrenal suppression [see WARNINGS AND PRECAUTIONS]
- Reduction in BMD [see WARNINGS AND PRECAUTIONS]
- Growth effects in pediatrics [see WARNINGS AND PRECAUTIONS]
- Glaucoma and cataracts [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adult And Adolescent Subjects Aged 12 Years And Older
The safety of ARNUITY ELLIPTA was evaluated in 10 double-blind, parallel-group, controlled trials (7 with placebo) of 8 to 76 weeks’ duration that enrolled 6,219 subjects with asthma. Doses of fluticasone furoate studied ranged from 25 to 800 mcg.
ARNUITY ELLIPTA 100 mcg was studied in 1,663 subjects, and ARNUITY ELLIPTA 200 mcg was studied in 608 subjects. Subject ages ranged from 12 to 84 years, 65% were female, and 75% were Caucasian.
In these trials, the proportion of subjects who discontinued study treatment early due to adverse reactions was 2% for subjects treated with both ARNUITY ELLIPTA 100 mcg and ARNUITY ELLIPTA 200 mcg and ≤1% for placebo-treated subjects. Serious adverse events, whether considered drug-related or not by the investigators, that occurred in more than 1 subject and in a greater percentage of subjects treated with ARNUITY ELLIPTA than placebo included hypertension, abscess, breast cancer, traumatic limb amputation, subarachnoid hemorrhage, and intervertebral disc protrusion; all events occurred at rates ≤1%.
The incidence of adverse reactions associated with ARNUITY ELLIPTA 100 mcg is shown in Table 1 and is based on one 24-week trial (Trial 1) in adult and adolescent subjects with asthma.
Table 1. Adverse Reactions with ARNUITY ELLIPTA 100 mcg with ≥3% Incidence and
More Common than Placebo (Trial 1, Intent-to-Treat Population)
|Adverse Reaction||ARNUITY ELLIPTA 100 mcg
(n = 114)
(n = 115)
|Upper respiratory tract infection||6||5|
The incidence of adverse reactions associated with ARNUITY ELLIPTA 200 mcg is shown in Table 2 and is based on one 24-week trial (Trial 3) in adult and adolescent subjects with asthma.
This trial did not have a placebo arm.
Table 2. Adverse Reactions with ARNUITY ELLIPTA 200 mcg with ≥3% Incidence (Trial
3, Safety Population)
|Adverse Reaction||ARNUITY ELLIPTA
(n = 119)
(n = 119)
|Upper respiratory tract infection||6||2|
Adverse reactions observed in the other trials were consistent with those described in Tables 1 and 2.
Long-term safety data are based on 2 trials in adult and adolescent subjects with asthma. In one 52-week trial, subjects received fluticasone furoate 100 mcg (n = 201) or fluticasone furoate 200 mcg (n = 202) in combination with a LABA. Subjects had a mean age of 39 years (adolescents made up 16% of the population), 63% were female, and 67% were Caucasian. In addition to the events shown in Table 1 and Table 2, adverse events occurring in ≥3% of the subjects treated with fluticasone furoate 100 mcg or fluticasone furoate 200 mcg, in combination with a LABA, included pyrexia, extrasystoles, upper abdominal pain, respiratory tract infection, diarrhea, and allergic rhinitis.
In a second 24- to 76-week trial, subjects received fluticasone furoate 100 mcg (n = 1,010). Subjects participating in this trial had a history of 1 or more asthma exacerbations that required treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization for the treatment of asthma within the previous 12 months. Subjects had a mean age of 42 years (adolescents made up 14% of the population), 67% were female, and 73% were Caucasian. In addition to the events shown in Table 1 and Table 2, adverse events occurring in ≥3% of subjects treated with fluticasone furoate 100 mcg for up to 76 weeks included allergic rhinitis, nasal congestion, and arthralgia.
Pediatric Subjects Aged 5 To 11 Years
The safety data for pediatric subjects is based upon one 12-week clinical trial that enrolled 593 subjects with asthma aged 5 to 11 years. Dosages of fluticasone furoate studied were 25, 50, or 100 mcg administered once daily. ARNUITY ELLIPTA 50 mcg was studied in 120 subjects (46 females and 74 males) [see Clinical Studies]. Adverse reactions (≥3% and greater than placebo) seen in pediatric subjects were similar to those reported in adult and adolescent subjects. Adverse reactions occurring in ≥3% of subjects treated with ARNUITY ELLIPTA 50 mcg and greater than placebo were pharyngitis, bronchitis, and viral infection.
Read the entire FDA prescribing information for Arnuity Ellipta (Fluticasone Furoate Inhalation Powder)